Hypomelanotic Disorder
Symptoms, Doctors, Treatments, Advances & More

Hypomelanotic Disorder Overview

Save information for later
Sign Up

Learn About Hypomelanotic Disorder

What is the definition of Hypomelanotic Disorder?
Hypomelanotic disorder is a term that refers to types of skin conditions in which melanocytes (pigment cells) have a loss of pigment. Types of hypomelanotic disorders include vitiligo, ash leaf spots, and idiopathic guttate hypomelanosis, among others.
What are the symptoms of Hypomelanotic Disorder?
Symptoms of hypomelanotic disorders include loss of pigmentation that varies by the type of disorder. Symptoms of vitiligo include a complete loss of pigment in the skin that appears as well-delineated spots and patches. Symptoms of ash leaf spots include oval flattened areas of skin that lack pigment and angiofibromas on the face. Symptoms of idiopathic guttate hypomelanosis include small white flattened areas on sun-exposed skin areas.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Hypomelanotic Disorder?
Treatment for hypomelanotic disorders depends on the type. Treatment for vitiligo may include corticosteroids, tacrolimus, pimecrolimus, ultraviolet B and PUVA therapy, self-tanning creams, and skin grafting. Treatment for ash leaf spots may include laser therapy. Treatment for idiopathis guttate hypomelanosis is not necessary.
Who are the top Hypomelanotic Disorder Local Doctors?
Elite in Hypomelanotic Disorder
Dr. Amit G. Pandya
Dermatology
Elite in Hypomelanotic Disorder
Dr. Amit G. Pandya
Dermatology

Sunnyvale Center (401)

401 Old San Francisco Road, Level 2, 
Sunnyvale, CA 
650-934-7676
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amit Pandya is a Dermatologist practicing medicine in Sunnyvale, California. Dr. Pandya is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Vitiligo, Hypomelanotic Disorder, Porphyria Cutanea Tarda, Melasma, and Thrombectomy. Dr. Pandya is board certified in Dermatology. Dr. Pandya is currently accepting new patients.

Elite in Hypomelanotic Disorder
Dr. John Harris
Dermatology
Elite in Hypomelanotic Disorder
Dr. John Harris
Dermatology

Hahnemann Campus

281 Lincoln St, 
Worcester, MA 
508-334-5979
Languages Spoken:
English
See accepted insurances

John Harris is a Dermatologist practicing medicine in Worcester, Massachusetts. Dr. Harris is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Vitiligo, Hypomelanotic Disorder, Bullae, and Cutaneous Lupus Erythematosus (CLE).

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hypomelanotic Disorder
Dr. Pearl Grimes
Dermatology
Elite in Hypomelanotic Disorder
Dr. Pearl Grimes
Dermatology

Office

5670 Wilshire Blvd Ste 650, 
Los Angeles, CA 
323-467-4389
Languages Spoken:
English
See accepted insurances

Pearl Grimes is a Dermatologist practicing medicine in Los Angeles, California. Dr. Grimes is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Vitiligo, Hypomelanotic Disorder, Melasma, and Tinea Versicolor.

View All Doctors
What are the latest Hypomelanotic Disorder Clinical Trials?
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
Enrollment Status: Recruiting
Publish Date: April 08, 2026
Intervention Type: Drug, Other
Study Phase: Phase 2

Summary: Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental f...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

View All Clinical Trials